297 related articles for article (PubMed ID: 27734632)
1. Is there a role for IGF-1 in the development of second primary cancers?
Shanmugalingam T; Bosco C; Ridley AJ; Van Hemelrijck M
Cancer Med; 2016 Nov; 5(11):3353-3367. PubMed ID: 27734632
[TBL] [Abstract][Full Text] [Related]
2. Impact of family history of cancer on risk and mortality of second cancers in patients with prostate cancer.
Chattopadhyay S; Hemminki O; Försti A; Sundquist K; Sundquist J; Hemminki K
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):143-149. PubMed ID: 30185889
[TBL] [Abstract][Full Text] [Related]
3. Role of insulin-like growth factor-1R system in colorectal carcinogenesis.
Donovan EA; Kummar S
Crit Rev Oncol Hematol; 2008 May; 66(2):91-8. PubMed ID: 17977741
[TBL] [Abstract][Full Text] [Related]
4. Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer.
Elbaz M; Ahirwar D; Ravi J; Nasser MW; Ganju RK
Oncotarget; 2017 May; 8(18):29668-29678. PubMed ID: 27213582
[TBL] [Abstract][Full Text] [Related]
5. Incidence of subsequent primary cancers and radiation-induced subsequent primary cancers after low dose-rate brachytherapy monotherapy for prostate cancer in long-term follow-up.
Vuolukka K; Auvinen P; Palmgren JE; Aaltomaa S; Kataja V
BMC Cancer; 2020 May; 20(1):453. PubMed ID: 32434560
[TBL] [Abstract][Full Text] [Related]
6. Association of First Primary Cancer With Risk of Subsequent Primary Cancer Among Survivors of Adult-Onset Cancers in the United States.
Sung H; Hyun N; Leach CR; Yabroff KR; Jemal A
JAMA; 2020 Dec; 324(24):2521-2535. PubMed ID: 33351041
[TBL] [Abstract][Full Text] [Related]
7. Risk of second primary cancers in individuals diagnosed with index smoking- and non-smoking- related cancers.
Adjei Boakye E; Wang M; Sharma A; Jenkins WD; Osazuwa-Peters N; Chen B; Lee M; Schootman M
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1765-1779. PubMed ID: 32356175
[TBL] [Abstract][Full Text] [Related]
8. Implications of insulin-like growth factor-I for prostate cancer therapies.
Kojima S; Inahara M; Suzuki H; Ichikawa T; Furuya Y
Int J Urol; 2009 Feb; 16(2):161-7. PubMed ID: 19183230
[TBL] [Abstract][Full Text] [Related]
9. Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study.
Park SM; Lim MK; Jung KW; Shin SA; Yoo KY; Yun YH; Huh BY
J Clin Oncol; 2007 Oct; 25(30):4835-43. PubMed ID: 17947733
[TBL] [Abstract][Full Text] [Related]
10. The insulin-like growth factor system and cancer.
LeRoith D; Roberts CT
Cancer Lett; 2003 Jun; 195(2):127-37. PubMed ID: 12767520
[TBL] [Abstract][Full Text] [Related]
11. Effect of lycopene on insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor in prostate cancer cells.
Kanagaraj P; Vijayababu MR; Ravisankar B; Anbalagan J; Aruldhas MM; Arunakaran J
J Cancer Res Clin Oncol; 2007 Jun; 133(6):351-9. PubMed ID: 17219202
[TBL] [Abstract][Full Text] [Related]
12. Association of radiotherapy for stage I-III breast cancer survivors and second primary malignant cancers: a population-based study.
Shi J; Liu J; Tian G; Li D; Liang D; Wang J; He Y
Eur J Cancer Prev; 2024 Mar; 33(2):115-128. PubMed ID: 37669169
[TBL] [Abstract][Full Text] [Related]
13. DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells.
Le H; Arnold JT; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2006 May; 290(5):E952-60. PubMed ID: 16368782
[TBL] [Abstract][Full Text] [Related]
14. Clinical and sociodemographic risk factors associated with the development of second primary cancers among postmenopausal breast cancer survivors.
Bailey S; Ezratty C; Mhango G; Lin JJ
Breast Cancer; 2023 Mar; 30(2):215-225. PubMed ID: 36316601
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer.
Hartog H; Boezen HM; de Jong MM; Schaapveld M; Wesseling J; van der Graaf WT
Breast; 2013 Dec; 22(6):1155-60. PubMed ID: 23968866
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy.
Davison Z; de Blacquière GE; Westley BR; May FE
Neoplasia; 2011 Jun; 13(6):504-15. PubMed ID: 21677874
[TBL] [Abstract][Full Text] [Related]
17. Trends in Risks for Second Primary Cancers Associated With Index Human Papillomavirus-Associated Cancers.
Suk R; Mahale P; Sonawane K; Sikora AG; Chhatwal J; Schmeler KM; Sigel K; Cantor SB; Chiao EY; Deshmukh AA
JAMA Netw Open; 2018 Sep; 1(5):e181999. PubMed ID: 30646145
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis.
Alexia C; Fallot G; Lasfer M; Schweizer-Groyer G; Groyer A
Biochem Pharmacol; 2004 Sep; 68(6):1003-15. PubMed ID: 15313394
[TBL] [Abstract][Full Text] [Related]
19. Interaction of IGF signaling and the androgen receptor in prostate cancer progression.
Wu JD; Haugk K; Woodke L; Nelson P; Coleman I; Plymate SR
J Cell Biochem; 2006 Oct; 99(2):392-401. PubMed ID: 16639715
[TBL] [Abstract][Full Text] [Related]
20. A population-based comparison of second primary cancers in Germany and Sweden between 1997 and 2006: clinical implications and etiologic aspects.
Liu H; Hemminki K; Sundquist J; Holleczek B; Katalinic A; Emrich K; Jansen L; Brenner H;
Cancer Med; 2013 Oct; 2(5):718-24. PubMed ID: 24403237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
